RNS Number : 2890H
SkinBioTherapeutics PLC
02 December 2020
2 December 2020
SkinBioTherapeutics plc
Notice of Results
SkinBioTherapeutics plc's
(AIM: SBTX or the "Company") financial results for the twelve months to 30 June 2020 will be released on Friday 4 December 2020. The results will be available on the Company's website following release to the London Stock Exchange.
For more information please contact:
|
SkinBioTherapeutics plc
|
Tel: +44 (0) 161 468 2760
|
|
Stuart Ashman, CEO
Doug Quinn, CFO
|
|
|
Cenkos Securities plc
(Nominated Adviser & Broker)
|
Tel: +44 (0) 20 7397 8900
|
|
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
|
|
|
Instinctif Partners
|
Tel: +44 (0) 20 7457 2020
|
|
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis
|
SkinBio@instinctif.com
|
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in Manchester, UK. For more information, visit:
www.skinbiotherapeutics.com
.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
NORBBBDDSBGDGGD
|
